High Yield Value Stocks: 4%+ Dividend Yield with Low P/E
High yield plus low P/E is a powerful combination — it means the market is paying you to wait for the value thesis to play out.
Stoquity AI Committee1Theme Overview
High-yield value stocks typically outperform in late-cycle and recessionary environments as investors rotate from growth to income. These stocks provide a margin of safety through current yield while offering mean-reversion upside potential.
2Why Now?
With Treasury yields potentially peaking, the relative attractiveness of equity yield improves. Many high-yield names trade at multi-year valuation lows despite stable cash flows, creating asymmetric risk-reward.
3Screening Methodology
Screen for stocks with dividend yield > 4%, forward P/E below market average, and payout ratio sustainable from free cash flow.
Factors used: Dividend YieldValueCash FlowEarnings StabilityLeverage
4Top Picks (5 Stocks)
Thesis: 6.2% dividend yield with 18 years of consecutive increases. Trading at 9x forward earnings. Wireless subscriber growth stabilizing; fixed wireless (FWA) adding broadband customers.
Risks: Heavy debt from spectrum auctions ($120B+); fiber buildout capex requirements; wireless pricing competition.
Thesis: 4.8% yield at 7x forward earnings. New product launches (Camzyos, Opdualag, Sotyktu) ramping to offset Eliquis/Opdivo patent cliffs. Karuna acquisition adds schizophrenia pipeline.
Risks: Major patent cliff 2026-2028 (Eliquis, Opdivo); acquisition integration risk; pipeline execution dependency.
Thesis: 5.0% yield post-dividend cut, now well-covered by free cash flow. Fiber subscriber growth 25%+ YoY. Debt reduction ahead of schedule ($20B paid down since Warner spinoff).
Risks: Lead-clad cable remediation costs; wireless ARPU growth deceleration; capital intensity of fiber rollout.
Thesis: 5.8% yield at 10x forward earnings. Post-COVID revenue reset complete. Seagen acquisition adds oncology growth engine. Cost-cutting program targeting $4B in savings.
Risks: COVID revenue decline continued; Seagen integration execution; pipeline must deliver to justify acquisition premium.
Thesis: 7.5% yield at 10x earnings. Marlboro pricing power offsets volume declines. NJOY e-vapor gaining market share. Smoke-free product transition underway.
Risks: Secular cigarette volume decline; FDA regulatory risk on flavored products; ESG exclusion from many funds.
View compact comparison table
| Symbol | Name | Sector | Score | Market Cap |
|---|---|---|---|---|
| VZ | Verizon Communications | Telecom | 80 | $185B |
| BMY | Bristol-Myers Squibb | Pharmaceuticals | 79 | $110B |
| T | AT&T | Telecom | 77 | $165B |
| PFE | Pfizer | Pharmaceuticals | 76 | $150B |
| MO | Altria Group | Consumer Staples | 78 | $95B |
5Theme Risks
High yields can signal value traps — businesses in structural decline that will eventually cut dividends. Always verify that free cash flow comfortably covers the dividend and that the business has a viable path to revenue stabilization.
Stocks with above-average dividend yields and below-average P/E ratios have outperformed the market by 3.2% annually over 50-year periods (Fama-French data).
Screen stocks yourself
Use the same 24-factor scoring model that powers Stoquity portfolios.
Try the AI Screener →